| 1 |
BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
|
| 2 |
LÓPEZ M J, CARBAJAL J, ALFARO A L, et al. Characteristics of gastric cancer around the world[J]. Crit Rev Oncol Hematol, 2023, 181: 103841.
|
| 3 |
SMYTH E C, NILSSON M, GRABSCH H I, et al. Gastric cancer[J]. Lancet, 2020, 396(10251): 635-648.
|
| 4 |
GUAN W L, HE Y, XU R H. Gastric cancer treatment: recent progress and future perspectives[J]. J Hematol Oncol, 2023, 16(1): 57.
|
| 5 |
KÖRFER J, LORDICK F, HACKER U T. Molecular targets for gastric cancer treatment and future perspectives from a clinical and translational point of view[J]. Cancers (Basel), 2021, 13(20): 5216.
|
| 6 |
DELLAS C, LOSKUTOFF D J. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease[J]. Thromb Haemost, 2005, 93(4): 631-640.
|
| 7 |
LI S J, WEI X H, HE J Y, et al. Plasminogen activator inhibitor-1 in cancer research[J]. Biomed Pharmacother, 2018, 105: 83-94.
|
| 8 |
SAKAKIBARA T, HIBI K, KOIKE M, et al. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of gastric cancer[J]. Cancer Sci, 2006, 97(5): 395-399.
|
| 9 |
ZHANG Y, ZHANG Y L, CHEN H M, et al. Expression of Bmi-1 and PAI-1 in esophageal squamous cell carcinoma[J]. World J Gastroenterol, 2014, 20(18): 5533-5539.
|
| 10 |
ZHANG W W, XU J, FANG H H, et al. Endothelial cells promote triple-negative breast cancer cell metastasis via PAI-1 and CCL5 signaling[J]. FASEB J, 2018, 32(1): 276-288.
|
| 11 |
HONG C L, YU I S, PAI C H, et al. CD248 regulates Wnt signaling in pericytes to promote angiogenesis and tumor growth in lung cancer[J]. Cancer Res, 2022, 82(20): 3734-3750.
|
| 12 |
ZUBAC D P, WENTZEL-LARSEN T, SEIDAL T, et al. Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy[J]. BMC Urol, 2010, 10: 20.
|
| 13 |
OFFERSEN B V, PFEIFFER P, ANDREASEN P, et al. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis[J]. Lung Cancer, 2007, 56(1): 43-50.
|
| 14 |
LIN X, LIN B W, CHEN X L, et al. PAI-1/PIAS3/Stat3/miR-34a forms a positive feedback loop to promote EMT-mediated metastasis through Stat3 signaling in non-small cell lung cancer[J]. Biochem Biophys Res Commun, 2017, 493(4): 1464-1470.
|
| 15 |
PAVÓN M A, ARROYO-SOLERA I, TÉLLEZ-GABRIEL M, et al. Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients[J]. Oncotarget, 2015, 6(30): 29016-29033.
|
| 16 |
CONWAY E M, COLLEN D, CARMELIET P. Molecular mechanisms of blood vessel growth[J]. Cardiovasc Res, 2001, 49(3): 507-521.
|
| 17 |
GOMES-GIACOIA E, MIYAKE M, GOODISON S, et al. Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model[J]. Mol Cancer Ther, 2013, 12(12): 2697-2708.
|
| 18 |
GEIS T, DÖRING C, POPP R, et al. HIF-2α-dependent PAI-1 induction contributes to angiogenesis in hepatocellular carcinoma[J]. Exp Cell Res, 2015, 331(1): 46-57.
|
| 19 |
CHEN S J, LI Y Q, ZHU Y H, et al. SERPINE1 overexpression promotes malignant progression and poor prognosis of gastric cancer[J].J Oncol, 2022, 2022: 2647825.
|